OBJECTIVE: Fibroblast growth factor 21 (FGF21) is a metabolic regulator of glucose and lipid metabolism. The physiological role of FGF21 is not yet fully elucidated, however, administration of FGF21 lowers blood glucose in diabetic animals. Moreover, increased levels of FGF21 are found in obese and diabetic rodents and humans compared with lean/non-diabetic controls. METHODS: Adult male rhesus macaque monkeys were chronically maintained on a high-fat diet (HFD) or a standard diet (control, CTR). Plasma levels of FGF21, triglycerides and cholesterol were measured and body weight was record. Glucose-stimulated insulin secretion (GSIS) and glucose clearance was determined during an intravenous glucose tolerance test. Furthermore, expression of FGF21 and its receptors were determined in liver, pancreas, three white adipose tissues (WATs) and two skeletal muscles. RESULTS: A cohort of the high-fat fed monkeys responded to the HFD with increasing body weight, plasma lipids, total cholesterol, GSIS and decreased glucose tolerance. These monkeys were termed HFD sensitive. Another cohort of monkeys did not become obese and maintained normal insulin sensitivity. These animals were defined as HFD resistant. Plasma FGF21 levels were significantly increased in all HFD fed monkeys compared with the CTR group. The HFD-sensitive monkeys showed a significant increase in FGF21 mRNA expression in all examined tissues compared with CTR, whereas FGF21 expression in the HFD-resistant group was only increased in the liver, pancreas and the retroperitoneal WAT. In the WAT, the co-receptor b-klotho was downregulated in the HFD-sensitive monkeys compared with the HFD-resistant group. CONCLUSION: This study demonstrates that HFD changes FGF21 and FGF21 receptor expression in a tissue-specific manner in rhesus monkeys; differential regulation is moreover observed between HFD-sensitive and -resistant monkeys. Monkeys that maintain normal levels of the FGF21 co-receptor b-klotho in the WAT on HFD were protected toward development of dyslipidemia and hyperglycemia.
INTRODUCTION
Fibroblast growth factor 21 (FGF21) is a pleiotropic hormone-like protein and a metabolic regulator of glucose and lipid metabolism. [1] [2] [3] [4] [5] FGF21 is a member of an atypical fibroblast growth factor (FGF) subfamily, which also includes FGF19 and FGF23. The subfamily differs from the normal FGFs by lacking the conventional FGF heparin-binding domain, enabling them to diffuse away from their tissues of origin and function as endocrine regulators. 6, 7 FGF21 is highly expressed in the liver, pancreas and testis, 5, 8, 9 and to a lesser extent in skeletal muscle 10, 11 and adipose tissues. [12] [13] [14] [15] FGF21 mediates its effect through the three FGF receptor (FGFR) isotypes FGFR 1c, 2c and 3c, complexed with the essential co-receptor b-klotho. [16] [17] [18] [19] FGFR1c is considered to be the most important partner for b-klotho in FGF21 signaling. [20] [21] [22] Activation of FGFRs by FGF21 induces a signaling cascade with stimulation of extracellular signal-regulated kinase 1/2 and Akt, 4, 5 and in cultured mouse and human adipocytes FGF21 stimulates glucose uptake. 4 In rodents, activation of the peroxisome proliferator-activated receptor a (PPARa) induces hepatic FGF21 expression in response to prolonged fasting. 1, 3, 23 In mice fasted for 24 h, plasma and hepatic FGF21 expression were increased, 1 and in humans, 7 days of starvation also led to elevated levels of plasma FGF21. 24 Moreover, transgenic mice overexpressing FGF21 display increased gluconeogenesis, fatty acid oxidation and ketogenesis, 3, 25 indicating an important role in the adaption to fasting/starvation. Paradoxically, high-fat feeding also induced FGF21 in white adipose tissues (WAT) through peroxisome proliferator-activated receptor g (PPARg) activation. [13] [14] [15] [26] [27] [28] In humans, high-fat feeding for 5 days leads to more pronounced upregulation of plasma FGF21 (ref. 29 ) than 7 days of fasting.
Systemic administration of FGF21 in diabetic mice models (ob/ob, db/db, diet-induced obese) lowers blood glucose, triglycerides and total cholesterol. 4, [30] [31] [32] These beneficial effects have also been observed in rhesus monkeys (Macaca mulatta) treated with FGF21. 33, 34 The effect of FGF21 on WAT seems to have a crucial role in the effect on the metabolic parameters as both WAT-selective b-klotho and FGFR1 knockout mice lead to loss of metabolic effect of FGF21. 35, 36 FGF21 may be a candidate for treating hyperglycemia and dyslipidemia; however, several studies have shown elevated levels of FGF21 in obese and diabetic mice models. 13, 15, 37 In obese and diabetic patients, plasma FGF21 is also higher, and furthermore correlates with several factors involved in the metabolic syndrome, for example, non-alcoholic fatty liver disease and dyslipidemia. 15, [38] [39] [40] [41] The increased endogenous levels of FGF21 indicate that obesity could be a state of FGF21 resistance. This has been shown in obese mice where increased plasma FGF21 led to a decrease in WAT and hepatic FGF21 receptors and signaling. 42 However, FGF21 resistance can, despite downregulation of FGFR1c, 2c and b-klotho, be overcome in rodents. 43 Therefore, downregulation of FGFR1c, 2c and b-klotho does not lead to overt FGF21 resistance and diet-induced obese and ob/ob mice have a better response to FGF21 treatment in terms of glucose-and lipid-lowering effects than the wild-type mice. 43 Extensive species similarities have been reported between human and non-human primates as they both show a spontaneous development of obesity and type 2 diabetes. This has made the obese/diabetic rhesus monkeys an ideal model to study the effect of anti-obesity and anti-diabetic therapies. [44] [45] [46] Here, we show that, similar to humans and mice, FGF21 plasma and mRNA levels correlate positively with obesity in diet-induced obese rhesus monkeys. However, we demonstrate for the first time that in a tissue-specific manner, consumption of a high-fat diet (HFD), independent of glucose intolerance, causes rises in FGF21 and that this tissues-specific increase in FGF21 expression are observed between monkeys with and without development of glucose intolerance and dyslipidemia.
MATERIALS AND METHODS Animals
Tissues and blood samples used in this study were obtained from the Oregon National Primate Research Center (ONPRC) Obese Resource, from adult male rhesus macaque monkeys (Macaca mulatta) that were killed for other studies. For this study, we chose animals that had segregated into diet sensitive, becoming obese and insulin resistant, and diet resistant. The experimental group consisted of 15 monkeys (age 6-13; but only with an age difference of 1.5 years between each subgroup). One cohort of the animals was maintained on a control diet (CTR, 14.6% fat calorie diet, Test Diet, Richmond, IN, USA). Another cohort of the animals was chronically maintained on a HFD (36% fat calories, Test Diet). In addition, the HFD was supplemented with 500 ml of Kool-Aid þ 20% fructose three times a week. Lean and fat mass of the monkeys were determined with dexa scannings. Based on their relative change in body weight and insulin sensitivity, the high-fat fed monkeys were divided into two groups: a HFD-resistant group (n ¼ 5) that had body weights and glucose-stimulated insulin secretion (GSIS) within 2 s.d. of the CTR animals, and a HFD-sensitive group (n ¼ 5) that had significant increased body weight and GSIS. All animal care and procedures were done according to the Institutional Animal Care and Use Committee at the ONPRC at Oregon Health and Science University. For all studies, food intake was carefully recorded every day and water was provided ad libitum. Lights were on from 0700 to 1900 hours.
At the day of killing, the animals were sedated with ketamine HCL (20 mg kg -1 , intramuscular) and then deeply anesthetized with sodium pentobarbital (30 mg kg -1 , intravenous). For measurement of plasma FGF21, glucose and insulin levels as well as triglycerides, total cholesterol, low-density lipoprotein and high-density lipoprotein, blood was collected from the abdominal aorta in EDTA tubes and kept on ice until centrifugation within 0.5 h. Plasma triglyceride, cholesterol and highdensity lipoprotein levels were measured by Rhein Consulting Laboratories (Portland, OR, USA). Liver, pancreas, three WATs (subcutaneous, retroperitoneal and mesenteric) and two skeletal muscles (soleus and gastrocnemius) were removed, frozen in liquid nitrogen and stored at À 80 1C for later determination of mRNA expression levels.
Glucose tolerance test
For glucose tolerance test, which was conducted pre-necropsy, the monkeys were fasted overnight with free access to drinking water. Animals were sedated with Telazol (3 mg kg -1 ) and a baseline blood sample was collected from the lateral saphenous vein. Subsequent, a bolus of 50% sterile dextrose (0.6 g kg FGF21 plasma levels were measured using a commercial FGF21-specific human ELISA kit (BioVendor, Prague, Czech Republic). Plasma samples were diluted 1:1 and analyzed according to the manufacturer's instructions. The sensitivity was 7.0 pg ml -1 and both the intra-and interassay variability was 4.0%. We only had plasma samples from a total of three in each group for these measurements.
Quantitative real-time PCR analysis
Total RNA was extracted from liver, pancreas, WAT and skeletal muscles using Trizol (Invitrogen, Carlsbad, CA, USA) and RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Complementary DNA was synthesized using iScript reverse transcription kit (Bio-Rad, Hercules, CA, USA). Quantitative real-time PCR was performed on an ABI 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using a LNA (locked nucleic acid) probe-based system from Roche (Mannheim, Germany). Primers were designed using Primer3 software 47 (Supplementary Table 1 ). All samples were run in triplicate and expression was calculated using the DDC T method. Samples were normalized to glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein L13a expression. We were only able to obtain a total of 3-4 of the tissues from each group.
Statistical analysis
Data are presented as mean±s.e.m. Statistical comparison among the groups was made using one-way analysis of variance followed by Tukey's multiple comparison test were appropriate. The correlation studies were evaluated by regression analysis. Data were analyzed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA), and the results were considered statistical significant for Po0.05.
RESULTS
The effect of HFD on body weight, plasma lipids, glucose and insulin levels The aim of this study was to investigate whether HFD has an effect on FGF21 levels in plasma and in metabolic relevant tissues in rhesus monkeys. Similar to observations in humans, monkeys chronically maintained on the HFD have a broad distribution of weight gain and insulin sensitivity. For this study, we have grouped cohorts of animals based on their relative changes in body weight and insulin sensitivity. HFD-resistant animals were defined as animals chronically maintained on HFD that have body weights and GSIS within 2 s.d. of the controls. Based on these The effect of HFD on FGF21 Plasma FGF21 levels were significantly increased B12-and 18-fold in the HFD-resistant and -sensitive group, respectively, compared with the CTR monkeys (Figure 3a) . The HFD-resistant monkeys tended to weigh slightly more than the CTR group, although this was not significant, and FGF21 plasma levels correlated positively with body weight (R 2 ¼ 0.9, Po0.0005, Figure 3c ).
The increase in plasma FGF21 could arise from various tissues, and therefore tissues where high FGF21 expression has been observed 8 were analyzed for FGF21 expression. In the liver, FGF21 mRNA expression was increased in both the HFD-resistant and -sensitive group compared with the CTR monkeys. Moreover, a strong correlation was detected between plasma FGF21 and hepatic mRNA expression of FGF21 (R 2 ¼ 0.8, Po0.002, Figure 3d ). To determine whether downregulation of FGF21 receptors was found in response to increased plasma FGF21, expression of the signaling receptor FGFR1, 2, 3 and the co-receptor b-klotho were determined. In all the tissues studied, no significant difference was observed in mRNA levels of FGFR2 and 3 between the three groups (data not shown). Nor in the liver were any differences found in FGFR1 and b-klotho expression between the three groups (data not shown).
FGF21 mRNA levels were also studied in pancreas, where significant upregulated levels were observed in both the HFDresistant and -sensitive monkeys compared with the CTR group; however, the FGF21 mRNA was significantly elevated in HFDsensitive compared with the HFD-resistant group (Po0.01; Figure 4a ). As a point of reference, FGF21 mRNA levels in the CTR monkeys were approximately sixfold higher in the pancreas compared with the liver (Figure 4b) , and indicate that pancreas might be a major contributor of plasma FGF21. In the pancreas, FGFR1 mRNA expression was significantly downregulated in the HFD-resistant and -sensitive monkeys compared with the CTR group (Figure 4c) , however, the mRNA expression of b-klotho was only slightly and not significantly decreased (Figure 4d ). Similar to hepatic FGF21 mRNA expression, pancreatic FGF21 mRNA expression also correlated positively with plasma FGF21 levels (R 2 ¼ 0.6, Po0.015, Figure 4e) . In contrast to other the tissues investigated, FGF21 mRNA expression in the subcutaneous WAT was specifically upregulated only in the HFD-sensitive animals (Figure 5a ). In the retroperitoneal WAT, FGF21 mRNA levels in both the HFD-resistant and -sensitive group were increased, and furthermore a significant increase in FGF21 mRNA was observed in the HFD-sensitive compared with the HFD-resistant monkeys (Figure 5b ). In the mesenteric WAT, a significant increase in FGF21 mRNA expression was observed in the HFD-sensitive monkeys compared with the CTR group (Figure 5c ). Furthermore, a comparison between the three WATs showed that the subcutaneous adipose tissue contained the highest expression of FGF21 mRNA levels (Figure 5d ). Measurement of FGFR1 expression in the three WATs showed no significant difference between the three groups (data not shown). However, b-klotho mRNA expression was significantly downregulated in the HFD-sensitive monkeys compared with both the CTR and the HFD-resistant groups in the subcutaneous WAT (Figure 5e ). In the retroperitoneal WAT, b-klotho mRNA was decreased in the HFD-sensitive compared with the HFD-resistant group, but only a tendency to a decrease is observed in the HFDsensitive compared with the CTR monkeys (Figure 5f ).
In soleus and gastrocnemius skeletal muscle, we found that FGF21 mRNA expression was significantly upregulated specifically Figure 3 . Effect of HFD on plasma and hepatic FGF21. FGF21 (a) plasma levels and (b) liver mRNA expression in male rhesus monkeys on control diet or a HFD to which they were either resistant or sensitive, n ¼ 3-4 per group. Data are means±s.e.m.; *Po0.05, **Po0.01 versus control fed rhesus macaques. Relationship between FGF21 plasma levels and (c) body weight (R 2 ¼ 0.9, Po0.0005, n ¼ 9), and (d) FGF21 liver mRNA (R 2 ¼ 0.8, Po0.002, n ¼ 9) in rhesus monkeys was determined with linear regression analysis. mCTR monkeys, & HFD-resistant monkeys, K HFD-sensitive monkeys.
in the HFD-sensitive monkeys compared with both the CTR and the HFD-resistant group (Supplementary Figures 1A and B) . Moreover, no difference was observed between FGF21 mRNA levels in the CTR and HFD-resistant group. FGFR1 and b-klotho mRNA expression were very low in both the soleus and gastrocnemius muscle and showed no significant difference between the three groups (data not shown).
To examine if the decrease in b-klotho in subcutaneous WAT of the HFD-sensitive monkeys has any downstream effect on FGF21 signaling early growth response-1 was measured. As shown in Figure 6a , early growth response-1 was significantly decreased in HFD-sensitive monkeys compared with the CTR group. Furthermore, PPARg (Figure 6b ), involved in insulin sensitivity, as well as adrenoreceptor beta 3 ( Figure 6c ) were significantly decreased in the HFD-sensitive monkeys. Expression of UCP1 in subcutaneous WAT was undetectable in the monkeys independent of the diet (data not shown).
In summary, the HFD-sensitive monkeys showed a significant increase in the FGF21 mRNA expression in all examined tissues (liver, pancreas, WATs and skeletal muscles) compared with CTR, whereas FGF21 expression in the HFD-resistant group was only increased in the liver, pancreas and the retroperitoneal WAT (see overview in Figure 7 ). FGFR1 mRNA expression is downregulated in the pancreas in both the HFD-sensitive and -resistant monkeys compared with the CTR group. b-Klotho mRNA levels are reduced in the subcutaneous WAT leading to decreased early growth response-1, PPARg and adrenoreceptor beta 3 expression in the HFD sensitive but not the resistant monkeys.
DISCUSSION
In this study, we have characterized two cohorts of rhesus monkeys who were fed a HFD, with one group being relatively resistant to the HFD and another cohort displaying obesity, insulin resistance and glucose intolerance. These animals also display increased triglycerides and cholesterol; all of these characteristics are consistent with previously published data in human subjects. 44 The reason for the observed difference in adiposity between monkeys fed the same diet is unknown, but in this study the highest FGF21 levels were observed in the HFD-sensitive monkeys. As mentioned above, studies have shown that FGF21 administration corrects dyslipidemia, 4, 30, 31, 33, 34 however, in this study the HFD-sensitive monkeys both had high FGF21, cholesterol and triglyceride levels indicating that FGF21 might be secreted as a compensatory mechanism, however, a state of FGF21 resistance has been described in diet-induced obese mice 42 and despite the ability of pharmacological doses of FGF21 to overcome this, 43 the endogenous level of FGF21 might not be high enough to activate the receptors. Furthermore, the strong positive correlation demonstrated between body weight and the FGF21 plasma levels, is consistent with previous studies in obese and diabetic patients. In rodents, the highest FGF21 mRNA levels have been observed in the pancreas followed by the liver. 5, 8, 9 In this study, an approximately sixfold higher FGF21 mRNA expression was present in the pancreas compared with the liver of the CTR monkeys, which is again consistent with the expression pattern of FGF21 observed in mice. 8 The role of FGF21 in pancreas is still not fully understood and autocrine/paracrine action of FGF21 on pancreatic cells might exist as studies have shown that FGF21 protects b-cell function and survival and inhibits glucagon secretion. 5, 48 FGF21 mRNA levels in the pancreas and the liver also correlated well with the FGF21 plasma levels, that is, FGF21 mRNA was upregulated in both the HFD-resistant and -sensitive group compared with the CTR monkeys, and therefore, both the pancreas and the liver could contribute to the increased plasma FGF21 levels. The exact role of FGF21 expressed in the various tissues is not known, but as the liver does not express FGFR1 (ref. 49 ) it does not seem to be a direct target of FGF21, and FGF21 expressed in the liver probably functions in an endocrine manner.
The high expression of FGF21 in the pancreas also point toward an endocrine role, but FGF21 receptors are expressed on b cells, and thus pancreatic FGF21 might function in both an endocrine and paracrine manner. FGF21 expression in the FGF21-responsive WAT is quite low and FGF21 from this tissue is thought to function in an autocrine manner. 26, 50 However, from this study it is not possible to conclude which tissues is the major contributor to plasma FGF21. In humans, who were fed a HFD for 5 days, a significant increase in plasma FGF21 was observed, 51 but no increased expression of FGF21 was observed in skeletal muscle or WAT pointing toward the liver and pancreas as major contributors to plasma FGF21.
No significant differences were observed in the FGF receptors in the liver; which, is in agreement with a study in diet-induced mice, were no reduction in b-klotho was observed in the liver. 42 This may also indicate that the liver is not a direct target of FGF21. In the pancreas, however, FGFR1 expression was significantly downregulated in the both the HFD-resistant and -sensitive FGF21 is upregulated in obese rhesus monkeys EB Nygaard et al monkeys, and thus cannot explain the differences observed in FGF21 expression between these two groups.
In all three WATs investigated, FGF21 mRNA expression was very low compared with the pancreas and the liver. The subcutaneous WAT was found to have the highest levels of FGF21 mRNA of the three WATs studied. Importantly, in the subcutaneous WAT the FGF21 mRNA expression was only increased in the HFD-sensitive group. This observation is interesting as it has previously been observed that FGF21 expression in the subcutaneous WAT in obese humans correlated with plasma FGF21 levels 15 and high local concentrations around one of FGF21's most important target tissues might lead to downregulation of FGF21 receptors. Furthermore, the fact that we observed downregulation of b-klotho in the subcutaneous WAT of the HFD-sensitive monkeys points toward a degree of FGF21 resistance. In diet-induced obese mice, FGF21 resistance was more pronounced in the WAT than in the liver, 42 supporting our findings. In rodents, administration of FGF21 to diet-induced obese mice lead to increased expression of UCP1 in subcutaneous WAT, 52 which could potentially increase the energy expenditure and prevent obesity. However, the effect on body weight in the diabetic obese monkeys treated with FGF21 was minor, although significant. The energy expenditure has not been studied in the monkeys and a change in food intake might also have caused the weight loss. 33 Several studies have shown that FGF21 is induced by PPARg agonists in WAT. [13] [14] [15] Despite the fact that PPARg target genes are fully activated in obese and diabetic patients, administration of PPARg agonist commonly reduces fasting plasma insulin and improves insulin resistance. 53 Moreover, a recent study showed that induction of FGF21 by the PPARg agonist rosiglitazone in WAT, did not contribute to the circulating levels of FGF21. 13, 26 This could, however, be explained by several factors, for example, (1) glucose is also a regulator of hepatic FGF21, and lower levels of glucose will reduce hepatic FGF21, (2) FGF21 in WAT is not the major contributor to circulating FGF21. In this study, the increased expression of FGF21 in WAT does not correlate with the PPARg expression; the opposite is actually observed but more than the expression level determines the activity of PPARg. The decreased expression of adrenoreceptor beta 3 could point toward a decreased responsiveness to catecholamines and might indicate impaired adaptive thermogenesis.
The expression of FGF21 mRNA determined in the skeletal muscles was very low, and the action of FGF21 in skeletal muscle is unclear as the expression of b-klotho is very limited in the skeletal muscle. 10, 11 Therefore, the expression of FGF21 in skeletal muscles does not support an autocrine function, although one study has shown an effect of FGF21 on glucose uptake in human skeletal muscle in vitro. 54 The regulation of FGF21 is complex and involves autocrine, paracrine and endocrine functions (see suggested overview in Figure 7 ). Results obtained in this study show that upregulation of FGF21 in diet-induced obese rhesus monkeys is in agreement with published human data, 15, 38, 40 but as tissue expression of FGF21 and receptors is commonly not examined, this study add much more information to understanding the role of FGF21 and its receptors. Elevated FGF21 levels potentially leading to FGF21 resistance in diet-induced obese rhesus monkeys, together with published data showing that obese diabetic rhesus monkeys can be beneficially treated with FGF21 administration, indicate that FGF21 resistance likely also can be overcome in humans. Of important interest is the finding that HFD-resistant monkeys seem to have preserved FGF21 sensitivity in the WAT, as no downregulation of b-klotho is observed. This is further supported by the observed downregulation of b-klotho in both the subcutaneous and retroperitoneal WAT of the HFD-sensitive monkeys (see overview in Figure 7) . The findings were supported by the decrease in early growth response-1 mRNA expression FGF21 is upregulated in obese rhesus monkeys EB Nygaard et al observed in subcutaneous WAT of HFD-sensitive monkeys. This indicates that the HFD-resistant monkeys are more FGF21-sensitive than the HFD-sensitive monkeys. In conclusion, in a tissue-specific manner, consumption of a HFD, independent of glucose intolerance, causes rises in FGF21 and this tissues-specific increase in FGF21 expression are observed between monkeys with and without development of glucose intolerance and dyslipidemia. FGF21 sensitivity in WAT might protect toward development of impaired glucose tolerance and dyslipidemia, but does not rule out that other factors might be involved as well. Thus, this study elucidates the importance of understanding the mechanisms regulating FGF21 resistance and supports a role for FGF21 as a new target in therapeutic therapy of obesity. Figure 7 . Overview of the mRNA expression in rhesus macaque monkeys on HFD. FGF21 mRNA expression is elevated in liver, pancreas, skeletal muscles and WATs in HFD-sensitive monkeys. HFD-resistant monkeys also have elevated FGF21 mRNA levels in liver and pancreas, but no significant difference was found in the WATs and skeletal muscles on FGF21 mRNA expression compared with the control fed monkeys. b-Klotho (b-Kl) mRNA expression was downregulated in the HFD-sensitive monkeys in the subcutaneous and retroperitoneal WAT, but not in any other tissue. Early growth response-1 (EGR1), PPARg and adrenoreceptor beta 3 (ADRB3) mRNA levels were downregulated in subcutaneous WAT in the HFD-sensitive monkeys. HFD-resistant monkeys also have downregulated PPARg mRNA levels in the subcutaneous WAT compared with the control fed monkeys. FGF21 from liver and pancreas might contribute to the elevated plasma FGF21 levels found in the rhesus macaque monkeys on HFD, whereas FGF21 in the WATs might exert autocrine or paracrine actions. ND, not determined; NS, nonsignificant.
